1080.5500 14.80 (1.39%)
NSE Mar 19, 2025 15:31 PM
Volume: 49,302
 

1080.55
1.39%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Alivus Life Sciences Ltd. is trading above all available SMAs
More from Alivus Life Sciences Ltd.
Recommended